Monday, March 05, 2018 10:15 PM ET
Insider Selling at Blueprint Medicines (BPMC) Continues with Significant Sale
There was a notable sale of shares of Blueprint Medicines by an insider today, as indicated in a form 4 document filed with the SEC. One insider — Dr Nicholas Lydon, Director — disposed of 25,000 shares in the company having a market value of approximately $2,197,356. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the disposition of 36,250 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 61,250 shares and have averaged 20,417 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at Blueprint Medicines is above its 191-company peer group average. The Biotechnology & Medical Research peer group saw 184 buy/sell trades during this period for an average of 1.0 transactions per company. However, the number of shares traded per transaction by Blueprint Medicines insiders is lower than its peers. Within the peer group there were 11,078,283 shares purchased and 12,894,504 shares sold with company insiders having sold 9,871 shares on average over this time period.
The data obtained in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.